"Moldova Pharmaceuticals & Healthcare Report Q3 2011" now available at Fast Market Research

July 10, 2011 - PRLog -- BMI View: Moldova's pharmaceutical market is tiny in absolute terms, although over the next five years we expect it to post respectable US dollar average annual growth rates of just under 8%. The country's move to cap wholesale and retail markets and register pharmaceutical prices at the beginning of 2011 has had mixed results. It has not reduced prices by the 40% some officials had claimed and has, according to recent reports, reduced access to some imported medicines. The government, under Prime Minister Vlad Filat, has moved to adjust the insurance system and promised to build new healthcare infrastructure. The market is one of the most liberal in the CIS, but still hampered by poverty, small size and political instability.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/204754_moldova_pharmaceuticals_healthcare_report_q3_2011.aspx
------------------------------------------------------------

Headline Expenditure Projections

*  Pharmaceuticals: MLD2.7bn (US$184mn) to MLD2.3bn (US$186mn); -3.0% in local currency terms and +1.4% in US dollar terms. Forecast down from Q211 due to readjustment of base year forecasts.
 *  Healthcare: MLD8.7bn (US$702mn) to MLD9.7bn (US$772mn); +11.7% 9in local currency terms and +9.9% in Us dollars. Forecast virtually unchanged from Q211 due to macroeconomic factors.
 *  Medical devices: MLD507mn (US$41mn) to MLD560mn (US$45mn); +10.4% in local currency times and +8.6% in US dollar terms. Forecast virtually unchanged from Q211.


Business Environment Rating: Moldova continues to rank 19th out of 20 countries in our Central and Eastern Europe (CEE) coverage universe. The country's score in terms of Industry Rewards has improved since Q211. However, Moldova continues to rank near the bottom in terms of this score due to its status as Europe's poorest country, as well as its current austerity measures and continued uncertain economic outlook.

Key Trends & Developments

*  Conflicting reports about the efficacy of margin controls and mandatory pricing registration of medicines make it hard to assess whether the authorities have really succeeded in arresting the rapid growth in pharmaceutical prices in the country. Between January and May 2011, according to the Health Ministry, prices grew by just 0.76%, compared with 6.6% growth in 2009-2010 and 25% annual growth rates as recently as 2008. Nevertheless, these gains pale in comparison with earlier claims of a 14% cut in prices and predictions at the beginning of the year that prices could be reduced by up to 40%.
 *  Moldova is seeking to exploit the potential of phytotherapeutic products to provide its domestic pharmaceutical industry with a source of original drugs. Domestic agency Moldsilva is developing the sector, along with local market leader Farmaco and niche operator AV Murin & Co, Kommersant-MD reported in April.


BMI Economic View: Inflation ticked modestly upwards in March, with the consumer price index registering a rise of 5.8% year-on-year (y-o-y), up from the 5.5% print seen in February. With the Moldovan economy continuing to chug along after posting impressive growth of 6.9% in 2010, coupled with still elevated global commodity prices, we expect inflation to continue heading higher over the course of 2011. We forecast inflation to hit 7.0% y-o-y by end-year.

BMI Political View: We expect the process of reforms to the business environment in Moldova to remain protracted, despite EU threats to withhold aid. Indeed, we believe that the huge obstacles facing reformers and the ongoing political deadlock in the country will make meaningful progress extremely difficult.

Partial Table of Contents:

SWOT Analysis
- Moldova Pharmaceuticals And Healthcare Industry SWOT
Pharmaceutical Business Environment Ratings
- Table: Emerging Europe - Regional Pharmaceutical Business Environment Ratings, Q311
- Rewards
- Risks
Moldova - Market Summary
Regulatory Regime
- Intellectual Property Rights
- Counterfeit Pharmaceuticals
- Pricing Regime
- Reimbursement Regime
- International Trade Agreements
Industry Developments
- Epidemiology
- Table: Republic of Moldova - Top 10 Causes of Death
- Table: Republic of Moldova - Leading Causes Of Morbidity As % of Total Disease Burden
- Communicable Diseases
- Healthcare Sector
- Table: Moldova's Public Health Expenditure - Provided By National Office of Statistics 2010
- Primary Care
- Secondary Care
- Table: Moldova - Number of Hospitals*
- Compulsory Health Insurance
- Table: Republic of Moldova - Social Health Insurance (SHI) Contributions By Source (As % Of Total)
- Recent Health Insurance Developments
- Research and Development
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Health Expenditure Indicators 2007-2015
- Table: Government Health Expenditure Indicators 2007-2015
- Table: Private Health Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Sales Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Devices Market Forecast
- Table: Medical Device Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Imports & Exports Indicators 2007-2015
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecasts
Competitive Landscape
- Pharmaceutical Industry
- Table: Republic of Moldova - Top Ten Manufacturers by Value
- Table: Republic of Moldova - Top Ten Trade, INNs/Combinations and ATC Groups as Percentages of Total Market Value (2008)
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=2047...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.